Video

David Brandes, MD

Publish date: January 30, 2014

At the Southern Clinical Neurological Society's 41st Annual Meeting, David W. Brandes, MD, Discussed the Future of Alemtuzumab

 

Online-Only Materials

AttachmentSize
File Brandes.mp4.mp437.02 MB

Recommended Reading

New and Noteworthy Information—December 2013
ICYMI Multiple Sclerosis
Teriflunomide Is Safe and Effective for Patients With CIS—Main Results From the TOPIC Study
ICYMI Multiple Sclerosis
Repetitive TMS May Reduce Depression and Fatigue in Patients With MS
ICYMI Multiple Sclerosis
Risk Stratification May Mitigate Adverse Events Associated With Newer MS Drugs
ICYMI Multiple Sclerosis
Remyelination May Continue Despite Age in Patients With MS
ICYMI Multiple Sclerosis
New and Noteworthy Information—January 2014
ICYMI Multiple Sclerosis
How Early Should MS Treatment Begin?
ICYMI Multiple Sclerosis
How Do Smoking and Epstein–Barr Virus Affect Risk of MS?
ICYMI Multiple Sclerosis
Glutamate Level Decreases Significantly in Patients With Secondary Progressive MS
ICYMI Multiple Sclerosis
IV Immunoglobulin Increases JCV Antibody Levels in Patients With MS
ICYMI Multiple Sclerosis